Verrica Pharmaceuticals

OverviewSuggest Edit

Verrica Pharmaceuticals develops and commercializes dermatological treatments. The Company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris.
TypePublic
Founded2013
HQWest Chester, US
Websiteverrica.com

Latest Updates

Employees (est.) (Dec 2019)17(+7%)
Share Price (May 2020)$13.9 (+16%)

Key People/Management at Verrica Pharmaceuticals

Paul Manning

Paul Manning

Chairman
Ted White

Ted White

President & CEO
Gary Goldenberg

Gary Goldenberg

Director
Mark Prygocki

Mark Prygocki

Director
Sean Stalfort

Sean Stalfort

Director
Craig Ballaron

Craig Ballaron

Director
Show more

Verrica Pharmaceuticals Office Locations

Verrica Pharmaceuticals has an office in West Chester
West Chester, US (HQ)
10 N High St #200
Show all (1)

Verrica Pharmaceuticals Financials and Metrics

Verrica Pharmaceuticals Revenue

USD

Net income (Q1, 2020)

(9.8m)

EBIT (Q1, 2020)

(9.9m)

Market capitalization (27-May-2020)

357.8m

Closing stock price (27-May-2020)

13.9

Cash (31-Mar-2020)

54.5m

EV

350.9m
Verrica Pharmaceuticals's current market capitalization is $357.8 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

9.1m14.6m

R&D expense

12.8m15.4m

Operating expense total

21.9m30.1m

EBIT

(21.9m)(30.1m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

2.5m3.7m3.5m3.6m3.5m5.0m

R&D expense

3.6m3.5m4.5m3.9m3.0m4.9m

Operating expense total

6.1m7.2m8.0m7.5m6.5m9.9m

EBIT

(6.1m)(7.2m)(8.0m)(7.5m)(6.5m)(9.9m)
Annual
USDFY, 2018FY, 2019

Cash

10.3m9.2m

Prepaid Expenses

1.3m3.0m

Current Assets

91.2m65.0m

PP&E

255.0k2.1m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

103.1m38.3m24.4m19.9m10.6m54.5m

Prepaid Expenses

1.4m1.7m1.4m985.0k3.0m2.3m

Current Assets

104.6m98.7m84.7m79.7m74.0m90.6m

PP&E

112.0k114.0k1.0m1.3m1.8m2.4m
Annual
USDFY, 2018FY, 2019

Net Income

(20.6m)(28.2m)

Depreciation and Amortization

20.3k64.2k

Accounts Payable

769.0k263.0k

Cash From Operating Activities

(17.9m)(27.4m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(7.8m)(14.6m)(7.5m)(14.5m)(20.6m)(9.8m)

Depreciation and Amortization

5.0k10.0k11.0k22.0k38.0k14.0k

Accounts Payable

573.0k914.0k215.0k33.0k89.0k(82.0k)

Cash From Operating Activities

(5.8m)(11.0m)(6.9m)(12.0m)(19.2m)(7.9m)
USDY, 2020

EV/EBIT

-35.5 x

EV/CFO

-44.4 x

Financial Leverage

1.7 x
Show all financial metrics

Verrica Pharmaceuticals Online and Social Media Presence

Embed Graph

Verrica Pharmaceuticals News and Updates

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

- New Drug Application for VP-102 for the treatment of molluscum contagiosum was accepted for filing by the U.S. Food and Drug Administration; assigned PDUFA goal date is July 13, 2020 -

Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank

WEST CHESTER, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine loan and security a…

Verrica Pharmaceuticals to Attend Several Upcoming Investor Conferences

WEST CHESTER, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will attend se…

Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102

- Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive -

Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

WEST CHESTER, Pa., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced t…

Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations

WEST CHESTER, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced i…
Show more

Verrica Pharmaceuticals Blogs

Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference

WEST CHESTER, Pa. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced

Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen

WEST CHESTER, Pa. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.  (“Verrica”) (Nasdaq: VRCA), announces with deep sadness the passing of Glenn Oclassen , a valued member of the Company’s Board of Directors. Mr. Oclassen passed away on November 13, 2019 .

Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results

Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results Content Import Wed, 11/06/2019 - 16:08 Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results November 6, 2019 at 4:05 PM EST This release is a backfill from a News Wire …

Verrica Pharmaceuticals Announces Leadership Team Update

WEST CHESTER, Pa. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.  (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference Content Import Wed, 08/28/2019 - 07:00 Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference August 28, 2…

Verrica Pharmaceuticals Reports Second Quarter 2019 Financial Results

-Achieved positive topline results from Phase 2 clinical trial of VP-102 in patients with common warts -Enrolled first patient in a Phase 2 trial of VP-102 for the treatment of external genital warts -NDA for molluscum contagiosum planned for second half of 2019 WEST CHESTER, Pa. , Aug.
Show more

Verrica Pharmaceuticals Frequently Asked Questions

  • When was Verrica Pharmaceuticals founded?

    Verrica Pharmaceuticals was founded in 2013.

  • Who are Verrica Pharmaceuticals key executives?

    Verrica Pharmaceuticals's key executives are Paul Manning, Ted White and Gary Goldenberg.

  • How many employees does Verrica Pharmaceuticals have?

    Verrica Pharmaceuticals has 17 employees.

  • Who are Verrica Pharmaceuticals competitors?

    Competitors of Verrica Pharmaceuticals include Urovant Sciences, Bellerophon Therapeutics and Deciphera Pharmaceuticals.

  • Where is Verrica Pharmaceuticals headquarters?

    Verrica Pharmaceuticals headquarters is located at 10 N High St #200, West Chester.

  • Where are Verrica Pharmaceuticals offices?

    Verrica Pharmaceuticals has an office in West Chester.

  • How many offices does Verrica Pharmaceuticals have?

    Verrica Pharmaceuticals has 1 office.